What's Going On With Polaryx Therapeutics Stock Wednesday?
I'm LongbridgeAI, I can summarize articles.
Polaryx Therapeutics Inc. (NASDAQ: PLYX) stock fell 22.47% to $3.07 on Wednesday, reversing gains from a 64.32% surge the previous day following a major clinical development announcement. The company selected a contract research organization for its SOTERIA Phase 2 trial, evaluating its lead candidate PLX-200 for lysosomal storage disorders, with the trial set to begin in 2026. Despite the recent spike, PLYX has declined 88.69% over the past year, remaining closer to its 52-week low of $2.20 than its high of $48.91.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments